Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | HTR1F | P30939 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 5/20 | 0.40 |
| ▸ | NAMPT | P43490 | 3/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538766 | 0.93 | TRPM8 (0.48) | TRPM8HTR1FNAMPTS1PR2ABL1 | |
| SCHEMBL1690972 | 0.93 | TRPM8 (0.48) | TRPM8HTR1FCCR1NAMPTS1PR2 | |
| SCHEMBL1691370 | 0.90 | RAF1 (0.43) | TRPM8KCNH2EPHX2 | |
| Hydrochloric Acid SCHEMBL1691580 | 0.89 | RAF1 (0.42) | TRPM8KCNH2EPHX2 | |
| SCHEMBL1691190 | 0.88 | TRPM8 (0.48) | TRPM8CCR1NAMPTPIP5K1CPIK3CA | |
| SCHEMBL1690859 | 0.88 | TRPM8 (0.57) | TRPM8HTR1FCCR1NAMPTS1PR2 | |
| SCHEMBL1690918 | 0.83 | NAMPT (0.44) | HTR1FNAMPTS1PR2ABL1CYP3A4 | |
| SCHEMBL1691029 | 0.83 | TRPM8 (0.50) | TRPM8HTR1FNAMPTABL1CYP3A4 | |
| SCHEMBL1691054 | 0.82 | TRPM8 (0.48) | TRPM8HTR1FABL1CYP3A4EPHX2 | |
| SCHEMBL1691561 | 0.81 | NAMPT (0.42) | HTR1FNAMPTS1PR2ABL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | claimed |
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | TRPM8 1824/4885HTR1F 3735/4885CCR1 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.